<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wong RA</submitter><funding>Cancer Research UK</funding><funding>Children&amp;apos;s Tumor Samuel Waxman Cancer Research Foundation Evelyn and Mattie Anderson</funding><funding>NCI NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>NIH</funding><pagination>709-718</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7024655</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>80(4)</volume><pubmed_abstract>The mTOR signaling is dysregulated prominently in human cancers including glioblastoma, suggesting mTOR as a robust target for therapy. Inhibitors of mTOR have had limited success clinically, however, in part because their mechanism of action is cytostatic rather than cytotoxic. Here, we tested three distinct mTOR kinase inhibitors (TORKi) PP242, KU-0063794, and sapanisertib against glioblastoma cells. All agents similarly decreased proliferation of glioblastoma cells, whereas PP242 uniquely induced apoptosis. Apoptosis induced by PP242 resulted from off-target cooperative inhibition of JAK2 and protein kinase C alpha (PKCα). Induction of apoptosis was also decreased by additional on-target inhibition of mTOR, due to induction of autophagy. As EGFR inhibitors can block PKCα, EGFR inhibitor</pubmed_abstract><journal>Cancer research</journal><pubmed_title>Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma.</pubmed_title><pmcid>PMC7024655</pmcid><funding_grant_id>P50 CA097257</funding_grant_id><funding_grant_id>A28592</funding_grant_id><funding_grant_id>U01CA217864</funding_grant_id><funding_grant_id>P30 CA082103</funding_grant_id><funding_grant_id>R01 CA221969</funding_grant_id><funding_grant_id>P50CA097257</funding_grant_id><funding_grant_id>R01NS091620</funding_grant_id><funding_grant_id>P30CA82103</funding_grant_id><funding_grant_id>CSC201806370104</funding_grant_id><funding_grant_id>R01CA221969</funding_grant_id><funding_grant_id>U01 CA176287</funding_grant_id><funding_grant_id>R01 NS091620</funding_grant_id><funding_grant_id>U01CA176287</funding_grant_id><funding_grant_id>U01 CA217864</funding_grant_id><pubmed_authors>Haas-Kogan DA</pubmed_authors><pubmed_authors>Lu M</pubmed_authors><pubmed_authors>An Z</pubmed_authors><pubmed_authors>Wong RA</pubmed_authors><pubmed_authors>Luo X</pubmed_authors><pubmed_authors>Phillips JJ</pubmed_authors><pubmed_authors>Shokat KM</pubmed_authors><pubmed_authors>Weiss WA</pubmed_authors><pubmed_authors>Fan QW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma.</name><description>The mTOR signaling is dysregulated prominently in human cancers including glioblastoma, suggesting mTOR as a robust target for therapy. Inhibitors of mTOR have had limited success clinically, however, in part because their mechanism of action is cytostatic rather than cytotoxic. Here, we tested three distinct mTOR kinase inhibitors (TORKi) PP242, KU-0063794, and sapanisertib against glioblastoma cells. All agents similarly decreased proliferation of glioblastoma cells, whereas PP242 uniquely induced apoptosis. Apoptosis induced by PP242 resulted from off-target cooperative inhibition of JAK2 and protein kinase C alpha (PKCα). Induction of apoptosis was also decreased by additional on-target inhibition of mTOR, due to induction of autophagy. As EGFR inhibitors can block PKCα, EGFR inhibitor</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Feb</publication><modification>2025-04-26T00:34:28.734Z</modification><creation>2025-04-06T09:45:27.555Z</creation></dates><accession>S-EPMC7024655</accession><cross_references><pubmed>31806641</pubmed><doi>10.1158/0008-5472.CAN-18-2808</doi><doi>10.1158/0008-5472.can-18-2808</doi></cross_references></HashMap>